Status:
COMPLETED
Identification of Risk Factors for Arrhythmia in Children and Adolescents With Hypertrophic Cardiomyopathy
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Hypertrophic Cardiomyopathy (HCM)
Eligibility:
All Genders
Up to 21 years
Brief Summary
This study will review medical information collected on children and adolescents with hypertrophic cardiomyopathy (HCM) to try to identify risk factors for arrhythmias (abnormal heart rhythms) in thes...
Detailed Description
Patients with HCM have an increased incidence of sudden death, particularly younger individuals. However, HCM has markedly variable clinical presentations, and the risk of sudden death and arrhythmia ...
Eligibility Criteria
Inclusion
- Children and adolescents (less than or equal to 21 years) with HCM who had been evaluated in the Cardiology Branch, National Heart Lung and Blood Institute between 1977 and 2002. HCM was diagnosed by echocardiographic demonstration of a hypertrophied non-dilated left ventricle (LV) in the absence of another cause of LV hypertrophy. All patients participated in protocols approved by the NHLBI Institutional Review Board, and provided informed written consent to participate. The patients participated in the following protocols: 98-H-0102, 77-H-0082, 99-H-0150, 01-H-0007, 96-H-0144, 94-H-0001, 84-H-0232, 98-H-0100, and 99-H-0065.
Exclusion
Key Trial Info
Start Date :
September 5 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 25 2012
Estimated Enrollment :
145 Patients enrolled
Trial Details
Trial ID
NCT00753233
Start Date
September 5 2008
End Date
January 25 2012
Last Update
July 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Heart, Lung and Blood Institute (NHLBI), 9000 Rockville Pike
Bethesda, Maryland, United States, 20892